Buscador de publicaciones<< Volver

Sambola A, Montoro JB, Del Blanco BG, Llavero N, Barrabés JA, Alfonso F, Bueno H, Cequier A, Serra A, Zueco J, Sabaté M, Rodríguez-Leor O, García-Dorado D

Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.

Am. Heart J.. 2013 Oct;166(4):669-75, PMID: 24093846

Oral anticoagulation (OAC) is the recommended therapy for patients with atrial fibrillation (AF) because it reduces the risk of stroke and other thromboembolic events. Dual antiplatelet therapy (DAPT) is required after percutaneous coronary intervention and stenting (PCI-S). In patients with AF requiring PCI-S, the association of DAPT and OAC carries an increased risk of bleeding, whereas OAC therapy or DAPT alone may not protect against the risk of developing new ischemic or thromboembolic events.

CARDIAC & CARDIOVASCULAR SYSTEMS

Descargar la publicación

Una iniciativa de

Ministerio de Economía y Competitividad Fondo Europeo de Desarrollo Regional IMIM - Parc de Salut Mar